Background

This study aims to establish and validate a nomogram as a predictive model in patients with new-onset atrial fibrillation (AF) after dual-chamber cardiac implantable electronic device (pacemaker) implantation.

Methods

A total of 1120 Chinese patients with new-onset AF after pacemaker implantation were included in this retrospective study. Patients had AF of at least 180/minute lasting 5 minutes or longer, detected by atrial lead and recorded at least 3 months after implantation. Patients with previous atrial tachyarrhythmias before device implantation were excluded. A total of 276 patients were ultimately enrolled, with 51 patients in the AF group and 225 patients in the non-AF group. Least absolute shrinkage and selection operator (LASSO) method was used to determine the best predictors. Through multivariate logistic regression analysis, a nomogram was drawn as a predictive model. Concordance index, calibration plot, and decision curve analyses were applied to evaluate model discrimination, calibration, and clinical applicability. Internal verification was performed using a bootstrap method.

Results

The LASSO method regression analysis found that variables including peripheral arterial disease, atrial pacing-ventricular pacing of at least 50%, atrial sense–ventricular sense of at least 50%, increased left atrium diameter, and age were important predictors of developing AF. In multivariate logistic regression, peripheral arterial disease, atrial pacing-ventricular pacing of at least 50%, and age were found to be independent predictors of new-onset AF.

Conclusion

This nomogram may help physicians identify patients at high risk of new-onset AF after pacemaker implantation at an early stage in a Chinese population.

ABI

ankle-brachial index

AF

atrial fibrillation

AP

atrial pacing

CIED

cardiac implantable electronic device

CIED-AF

cardiac implantable electronic device–detected atrial fibrillation

C-index

concordance index

HF

heart failure

LA

left atrial

LASSO

least absolute shrinkage and selection operator

OR

odds ratio

PAD

peripheral arterial disease

SCAF

subclinical atrial fibrillation

VP

ventricular pacing

VS

ventricular sense

Atrial fibrillation (AF) is the most common arrythmia in adults older than 40 years.1  Stroke is the most serious complication of AF and can triple the mortality rate in patients with AF. Each year, 16.9 million people worldwide experience stroke. The causes remain unexplained for approximately 20% to 40% of strokes.2  Between 10% and 30% of these unexplained stroke cases may be the result of a missed AF diagnosis.35  Cardiac implantable electronic device–detected AF (CIED-AF), which is a type of subclinical atrial fibrillation (SCAF), has attracted much attention in recent years, as it can increase the detection rate of AF episodes. Although different from clinical AF, SCAF, which often manifests as asymptomatic AF, has a strong predictive effect on clinical AF.6  Subclinical AF occurs frequently in older people. Cardiac implantable electronic devices help detect CIED-AF.7  The detected increase in AF load may lead to increased ischemic stroke, heart failure (HF), and mortality.810  Identifying patients with CIEDs at high risk of new-onset AF is important to prevent adverse clinical outcomes. The current diagnosis of AF relies mainly on clinical symptoms, electrocardiography, and other detection methods. However, AF is often paroxysmal and asymptomatic, which makes early effective and accurate detection of AF difficult. Therefore, establishment of an SCAF prediction model may help clinicians make effective interventions and have good therapeutic effect.

Age is a frequently reported independent predictor of CIED-AF.7,11  Some studies have also found that conditions such as hypertension, HF, and cerebral microvascular disease; CHADS2 (congestive HF, hypertension, age ≥75 years, and diabetes mellitus, stroke) and CHA2DS2-VASc (congestive HF, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65–74 years, sex category) scores; echocardiographic indicators including left atrial (LA) diameter and LA volume index; and pacemaker parameters such as ventricular pacing ratio may be predictors of CIED-AF.1014  However, their effectiveness in predicting the risk of CIED-AF is still controversial. Currently, there are no predictive tools to integrate and analyze the risk factors affecting CIED-AF.

Nomogram is a prognostic model that describes statistics in a graphical manner through biological clinical variables. It is a tool for prediction based on statistical data obtained from patients with diseases with identical characteristics. Each variable in the nomogram is given a value that represents its prognostic significance. Individualized risk can be estimated according to the patients' different clinical characteristics. The cumulative scores of all variables are matched with the result scale, and a value is obtained to estimate the specific results.1517  Compared with other predictive tools, nomogram is most accurate and has superior discriminative capability in predicting results.18  As an important tool for guiding modern medical decisions, nomogram has been widely used in the fields such as surgery, cancer, and myocardial infarction.1921  No previous research to date has reported use of nomogram as a predictive model for prediction of CIED-AF occurrence.

The purpose of this study was to identify independent predictors and establish a nomogram based on parameter integration to predict the probability of new-onset AF in patients after dual-chamber pacemaker implantation. The goal of this model is to help clinicians identify high-risk patients, control risk factors, and select reasonable treatment options for these patients.

Patient Selection

To evaluate the predictive ability and discrimination performance of nomograms, bootstrap verification (1000 bootstrap samples) was performed to calculate the concordance index (C-index). Patients with new-onset AF after CIED implantation7  at the cardiovascular department of Sir Run Run Shaw Hospital in Hangzhou, China, from January 1, 2017, to December 31, 2018, were included in the study. Patients were excluded if they had a history of AF or atrial flutter or other persistent supraventricular tachycardia lasting more than 5 minutes as confirmed by previous examination or if they had a history of cardiac surgery for congenital heart disease, valvular heart disease, or myocardial infarction. Patients were also excluded if they had an implanted single-chamber pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy-defibrillator/pacemaker or if they had undergone replacement of a CIED. Patients were divided into 2 groups based on whether new-onset AF was detected after pacemaker implantation (new-onset AF and non-AF groups). The inclusion and exclusion criteria are shown in Table I.22 

TABLE I

Key Inclusion and Exclusion Criteria

Key Inclusion and Exclusion Criteria
Key Inclusion and Exclusion Criteria

Data Collection

The following medical data were obtained from electronic medical records based on relevant demographic, clinical, and laboratory features. These features consist of general information, history, auxiliary examination, echocardiographic parameters, medication administration record, and pacemaker parameters. General information included age, sex, body mass index, and smoking and drinking status. Medical history included congestive HF, hypertension, coronary heart disease, peripheral arterial disease (PAD), diabetes, hyperlipidemia, cerebrovascular disease, chronic kidney disease, and chronic obstructive pulmonary disease. Peripheral arterial disease was previously diagnosis according to ankle-brachial index (ABI) of 0.9 or less, ABI of 1.4 or greater, or imaging evidence combined with clinical manifestations. Congestive HF was defined by moderate to severe systolic left ventricular dysfunction, left ventricular ejection fraction of 40% or less, or receiving medication to relieve symptoms of HF. Hypertension was defined by systolic blood pressure of 140 mm Hg or greater and/or diastolic blood pressure of 90 mm Hg or greater as measured 3 times in the same patient on different days or if the patient had a history of using antihypertensive drugs to control blood pressure. Diabetes was diagnosed according to fasting venous plasma glucose concentration of at least 7.0 mmol/L (126 mg/dL), random vein plasma glucose concentration of at least 11.1 mmol/L (200 mg/dL), or positive glucose tolerance test vein plasma glucose concentration of at least 11.1 mmol/L 2 hours after oral administration of 75 g of glucose and/or the use of insulin or oral hypoglycemic drugs. If a patient met any 1 of the 3 criteria, all 3 measurements were duplicated the following day.

Coronary heart disease included patients with known but untreated disease and those being treated with anti-platelet aggregation drugs and lipid-lowering drugs. Diagnosis of cerebrovascular disease was made according to the corresponding neurological symptoms and signs and from imaging evidence. The attack lasted more than 24 hours. Chronic kidney disease was diagnosed as basic kidney disease lasting more than 3 months with an estimated glomerular filtration rate less than or equal to 60 mL/min/1.73 m2. Chronic obstructive pulmonary disease was diagnosed according to a history of more than 2 years of cough, expectoration, asthma, and other respiratory symptoms, as well as lung function test airflow limitation (forced expiratory volume in 1 second/forced vital capacity <70%). Auxiliary examination included N-terminal prohormone of brain natriuretic peptide, estimated glomerular filtration rate, blood urea nitrogen, and high-sensitivity C-reactive protein. Echocardiographic parameters included left ventricular ejection fraction and LA diameter. Increased LA diameter was defined as 40 mm or greater for men and 38 mm or greater for women by echocardiography.23  Prior medication administration records included angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists, b-blockers, calcium channel blockers, lipid-lowering drugs, diuretics, and antiplatelet drugs. Pacemaker parameters included pacemaker manufacturer, type of electrode, and mode setting. CHADS2 and CHA2DS2-VASc scores were also included. The nominal pacemaker setting for paced atrioventricular intervals/sensed atrioventricular intervals delay is 180/150 ms with the atrioventricular interval optimization function on.

The primary outcome was new-onset AF (atrial rate ≥180 bpm detected by atrial lead) with duration of at least 5 minutes occurring at least 3 months after CIED implantation. Confirmation of AF diagnosis must have been made by at least 1 clinician, and CIED-AF was diagnosed according to guidelines from the European Society of Cardiology.24  Patients were followed up regularly at 1, 3, 6, 9, and 12 months after implantation. During follow-up, pacemaker parameters were recorded.

All participants provided written consent before entering the study. The study was approved by the medical ethics committees of Sir Run Run Shaw Hospital, affiliated with the Medical School of Zhejiang University, with the ethics approval No. keyan20180106-10.

Statistical Analysis

Data were analyzed using SPSS 25.0 software and R software version 3.6.0 (http://www.r-project.org). Categorical variables were compared by χ2 test and expressed as a number and percentage. Continuous variables with a normal distribution were compared by t test and expressed as mean (SD). Continuous variables with non-normal distribution were compared by Mann-Whitney U test and expressed as median (IQR).

The least absolute shrinkage and selection operator (LASSO) regression method for reducing high-dimensional data was applied to select the best predictor for new-onset AF in patients after dual-chamber pacemaker implantation. The LASSO regression was performed using the “glmnet” package of R software. Cross-validation was used to determine the adjustment parameter (λ) suitable for LASSO regression. The principle is that the sum of the absolute values of the negative log likelihood ratios must be smaller than the adjustment parameter λ. If λ is large, it has no effect on the estimated regression parameters, but as λ decreases, some coefficients may decrease to 0. Therefore, λ was chosen with the smallest cross-validation error. Finally, the model was refitted by using all the observed values and the selected λ. Most coefficients were reduced to 0, and the remaining nonzero coefficient variables were risk factors selected by LASSO. Subsequently, after combined consideration with the clinical significance of the variables, LASSO regression results, and sample size, final variables included in the model were determined.

The binary classification logistic regression was used to construct a prediction model. In logistic regression, the association between independent variables and clinical events was determined by 95% CI, odds ratio (OR), and P value. P < .05 was considered statistically significant.

Based on binary classification logistic regression, a nomogram was established to predict the probability of new-onset AF in patients with dual-chamber pacemakers. To evaluate the accuracy and discriminative ability of the nomogram, the C-index was calculated and a calibration curve constructed. The “rmda” package decision curve analysis chart in R software was used to quantify the net benefit under different threshold probabilities in patients with new-onset AF after dual-chamber pacemaker implantation to determine the clinical utility of the nomogram. Lift verification (1000 bootstrap samples) was applied for internal verification of the model.

Clinical Characteristics of the Study Cohort

The primary cohort included 1120 patients who underwent surgery for electronic device implantation in the cardiology department of Sir Run Run Shaw Hospital between January 2017 and December 2018. After screening according to the inclusion and exclusion criteria, 276 patients were ultimately enrolled, including 51 patients with new-onset AF and 225 patients without AF. Nineteen patients had incomplete medical records, 60 patients had irregular outpatient visits and lack of follow-up data, and 3 patients died within 1 year of follow-up, for a total of 82 patients who were excluded because of incomplete data or loss to follow-up (Fig. 1).

Fig. 1

Screening flow chart with inclusion and exclusion criteria.

AF, atrial fibrillation; CHD, coronary heart disease; CIED, cardiac implantable electronic device; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; HVD, heart valve disease; ICD, implantable cardioverter-defibrillator; SSI, single-chamber pacing and single-chamber sensing with inhibition; VVI, ventricular pacing and ventricular sensing with inhibition.

Fig. 1

Screening flow chart with inclusion and exclusion criteria.

AF, atrial fibrillation; CHD, coronary heart disease; CIED, cardiac implantable electronic device; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; HVD, heart valve disease; ICD, implantable cardioverter-defibrillator; SSI, single-chamber pacing and single-chamber sensing with inhibition; VVI, ventricular pacing and ventricular sensing with inhibition.

Close modal

Patients were followed up for a mean period of approximately 23.44 months. New-onset AF was detected in 51 patients (18.7%) after double-chamber pacemaker implantation, and 225 patients did not develop AF. The follow-up time for patients with new-onset AF was longer (23.5 months vs 21.0 months). The clinical characteristics between the 2 groups were compared, and the results showed a significant difference in age (P = .012) and history of PAD (P < .001). The average age of patients with new-onset AF was 72.9 years, which was significantly older than the non-AF group (68.8 years old). The incidence of PAD was significantly higher in the new-onset AF group than in the non-AF group (17.6% vs 4%). There were also significant differences in the pacing pattern between the 2 groups. In the group of patients with new-onset AF, atrial pacing (AP)–ventricular pacing (VP) ≥50% accounted for 19.6% of cases, which was higher than 8.0% in the group without AF (P = .014). Atrial pacing ≥50% and atrial sense (AS)–ventricular sense (VS) ≥50% were also statistically different between the 2 groups, with P values of .048 and .037, respectively. The percentage of AS-VS ≥50% in the new-onset AF group was 17.6%, and in the group without new-onset AF, the percentage was 32.4%. Thus, it was found that the population with less AS-VS ≥50% (which indicated a greater percentage of AP and/or VP) was more prone to new-onset AF. There was a negative correlation between AS-VS ≥50% and risk of new-onset AF. There were no significant differences between the 2 groups in sex, body mass index, or history of hypertension, diabetes, coronary heart disease, HF, and drug use. Descriptive statistics of the patients in this study are shown in Table II.

TABLE II

Patient Clinical Characteristics a

Patient Clinical Characteristics a
Patient Clinical Characteristics a

Feature Selection

The 28 independent variables assessed in this study were selected by the LASSO regression algorithm. When the most suitable tuning parameter λ was 0.036, the partial likelihood deviation reached the minimum value (Fig. 2A). At that time, 5 nonzero coefficient variables were retained in the LASSO analysis (Fig. 2B). The variable with the most predictive accuracy was PAD, followed by AP-VP ≥50%, AS-VS ≥50%, LA diameter, and age.

Fig. 2

Graphs show the selection of predictors using LASSO regression. The variable with the most predictive accuracy was peripheral artery disease, followed by atrial pacing–ventricular pacing of at least 50%, atrial sense–ventricular sense of at least 50%, increased left atrial diameter, and age. A) Cross-validation by the minimum parameters was used to determine the best parameters in the LASSO model. The 28 independent variables were selected using the LASSO regression algorithm. When the most suitable tuning parameter λ was 0.036, the partial likelihood deviation reached the minimum value. The 2 vertical dashed lines represent the lines with lowest error (left) and the fewest features (right). B) An effective diagram of curves generated by 28 features of LASSO coefficient. Five nonzero coefficient variables were retained in the LASSO analysis. The vertical dashed line represents the selected independent variable when λ as 0.036 is intercepted.

LASSO, least absolute shrinkage and selection operator.

Fig. 2

Graphs show the selection of predictors using LASSO regression. The variable with the most predictive accuracy was peripheral artery disease, followed by atrial pacing–ventricular pacing of at least 50%, atrial sense–ventricular sense of at least 50%, increased left atrial diameter, and age. A) Cross-validation by the minimum parameters was used to determine the best parameters in the LASSO model. The 28 independent variables were selected using the LASSO regression algorithm. When the most suitable tuning parameter λ was 0.036, the partial likelihood deviation reached the minimum value. The 2 vertical dashed lines represent the lines with lowest error (left) and the fewest features (right). B) An effective diagram of curves generated by 28 features of LASSO coefficient. Five nonzero coefficient variables were retained in the LASSO analysis. The vertical dashed line represents the selected independent variable when λ as 0.036 is intercepted.

LASSO, least absolute shrinkage and selection operator.

Close modal

Nomogram Construction and Performance

After combined analysis of the variables' clinical significance and LASSO regression results and after further assessment of whether the variables were colinear and crossover, 4 variables were used for logistic regression as initial independent variables: PAD, AP-VP ≥50%, increased LA diameter, and age. Logistic regression results showed that PAD (OR, 1.812 [95% CI, 0.917–3.585]; P < .001), AP-VP ≥50% (OR, 3.006 [95% CI, 1.242–7.279]; P = .015), and age (OR, 1.037 [95% CI, 1.004–1.072]; P = .029) were independent predictors (Table III). The predictive factors obtained above were integrated into a model through R language, and the results were visualized with a nomogram (Fig. 3).

TABLE III

Predictors of New-Onset AF in Patients With Dual-Chamber Pacemaker Implantation by Multifactor Logistic Regression

Predictors of New-Onset AF in Patients With Dual-Chamber Pacemaker Implantation by Multifactor Logistic Regression
Predictors of New-Onset AF in Patients With Dual-Chamber Pacemaker Implantation by Multifactor Logistic Regression
Fig. 3

This sample nomogram for calculating the risk of new-onset AF after dual-chamber pacemaker implantation takes a 65-year-old male patient with PAD as an example. The 65 years in the age line corresponds to a score of 50 in the points line, and the presence of PAD corresponds to a score of 70. If LAD is 42 mm, the corresponding score is 20. If AP-VP less than 50% is detected, the corresponding score is 0. The above-described scores are cumulative, so the total score for this patient is 140 points (50 + 70 + 20 + 0). Therefore, when a vertical line is drawn from the total score axis to the risk of new-onset AF axis, the result shows that the risk of new-onset AF is 50%.

AF, atrial fibrillation; AP-VP, atrial pacing–ventricular pacing; LAD, left atrial diameter; PAD, peripheral artery disease; .

Fig. 3

This sample nomogram for calculating the risk of new-onset AF after dual-chamber pacemaker implantation takes a 65-year-old male patient with PAD as an example. The 65 years in the age line corresponds to a score of 50 in the points line, and the presence of PAD corresponds to a score of 70. If LAD is 42 mm, the corresponding score is 20. If AP-VP less than 50% is detected, the corresponding score is 0. The above-described scores are cumulative, so the total score for this patient is 140 points (50 + 70 + 20 + 0). Therefore, when a vertical line is drawn from the total score axis to the risk of new-onset AF axis, the result shows that the risk of new-onset AF is 50%.

AF, atrial fibrillation; AP-VP, atrial pacing–ventricular pacing; LAD, left atrial diameter; PAD, peripheral artery disease; .

Close modal

Nomogram Example

Taking a 65-year-old male patient with a dual-chamber pacemaker and PAD as an example (Fig. 3), 65 years in the age line corresponds to a score of 50 in the points line, and the presence of PAD corresponds to a score of 70. If the patient is admitted to the hospital with an echocardiogram indicating an increased LA diameter of 42 mm, the corresponding score is 20. If AP-VP <50% is detected during pacemaker program-control follow-up, the corresponding score is 0. The above-mentioned scores are cumulative, so the total score for this patient is 140 points (50 + 70 + 20 + 0). Therefore, when a vertical line is drawn from the total score axis to the risk of new-onset AF axis, the result shows that the risk of new-onset AF is 50% (Fig. 3).

Verification of the Nomogram

The C-index for nomogram prediction was 0.726 (95% CI, 0.717–0.735) for the cohort (Fig. 4A), or 0.727 (95% CI, 0.651–0.800) through bootstrapping validation. The calibration curve of the nomogram for the risk of new-onset AF in patients with a dual-chamber pacemaker indicated that the predictions were highly consistent with the observed results. The above-described data showed that the model had good predictive ability (Fig. 4B).

Fig. 4

Evaluation of the discrimination and consistency of the predictive model of new-onset AF after dual-chamber pacemaker implantation, including A) receiver operating characteristic curve and B) calibration curve of the predictive model. Bootstrap verification (1000 bootstrap samples) was performed to calculate the concordance index. The x-axis represents predicted risk of new-onset AF, the y-axis represents actual risk of new-onset AF, the diagonal dashed lines represent the ideal model predictions, the solid lines represent the nomogram performance, and the diagonal dotted line indicates the ideal prediction.

AF, atrial fibrillation; AUC, area under the curve.

Fig. 4

Evaluation of the discrimination and consistency of the predictive model of new-onset AF after dual-chamber pacemaker implantation, including A) receiver operating characteristic curve and B) calibration curve of the predictive model. Bootstrap verification (1000 bootstrap samples) was performed to calculate the concordance index. The x-axis represents predicted risk of new-onset AF, the y-axis represents actual risk of new-onset AF, the diagonal dashed lines represent the ideal model predictions, the solid lines represent the nomogram performance, and the diagonal dotted line indicates the ideal prediction.

AF, atrial fibrillation; AUC, area under the curve.

Close modal

Clinical Value of the Nomogram

The clinical decision curve is a new method to evaluate the clinical application value of the predictive model. The decision curve analysis of the nomogram is presented in Figure 5. The nomogram predictive model established in this study had a higher clinical net benefit than the single-factor model of AP-VP ≥50% or increase in LA diameter. Therefore, the decision curve analysis confirmed the net benefits of the predictive nomogram.

Fig. 5

Clinical decision curve of a predictive model of new-onset AF after dual-chamber pacemaker implantation. The x-axis represents the threshold probability, the y-axis represents the net benefit, the red line represents the nomogram of new-onset AF after dual-chamber pacemaker implantation, the purple dotted line represents the LA diameter single-factor predictive model, the green dashed line represents the AP-VP ≥50% univariate predictive model, the solid light-gray line represents patients with new AF after dual-chamber pacemaker implantation, and the solid dark-gray line represents patients without AF.

AF, atrial fibrillation; AP-VP, atrial pacing–ventricular pacing; LA, left atrial; LAD, left anterior descending artery.

Fig. 5

Clinical decision curve of a predictive model of new-onset AF after dual-chamber pacemaker implantation. The x-axis represents the threshold probability, the y-axis represents the net benefit, the red line represents the nomogram of new-onset AF after dual-chamber pacemaker implantation, the purple dotted line represents the LA diameter single-factor predictive model, the green dashed line represents the AP-VP ≥50% univariate predictive model, the solid light-gray line represents patients with new AF after dual-chamber pacemaker implantation, and the solid dark-gray line represents patients without AF.

AF, atrial fibrillation; AP-VP, atrial pacing–ventricular pacing; LA, left atrial; LAD, left anterior descending artery.

Close modal

Cardiac implantable electronic device–detected AF is reported to be closely associated with stroke and HF.8,25  Whether the risk of CIED-AF is the same as for clinically observed AF is still controversial. Currently, there are no published guidelines or clinical trials to help clinicians make an evidence-based clinical decision for the prevention of CIED-AF.26  Also, there is no generally accepted predictive model of new-onset AF for patients with an implanted pacemaker. In this study, the authors aimed to establish and validate a predictive nomogram for predicting the risk of developing new-onset AF in patients with CIEDs. Considering that pacemaker implantation may induce surgery-related AF, combined with previous literature, AF recorded by pacemaker at least 3 months after implantation was chosen as the outcome event of this study.

It was reported that approximately 13% to 35% of patients with CIEDs may experience new-onset AF.13,25,27  In this study, the incidence of new-onset AF after dual-chamber pacemaker implantation was 18.7%, which was consistent with previous studies. The differences in the incidence of AF from various studies may be the result of differences in research backgrounds and methods of diagnosing AF. In addition, some studies did not exclude patients with a history of AF.

In this study, multivariate logistic regression analysis results revealed that PAD, AP-VP ≥50%, and age were independent predictors of new-onset AF after dual-chamber pacemaker implantation. Although LA diameter was not an independent predictor, LA diameter did play an important role in the progress of new-onset AF. This study used the LASSO method, a data dimensionality reduction method, which is suitable for the regression of large groups of clinical factors, selects variables for the sample data, and extracts the most important predictors by compressing the original coefficients to avoid overfitting.

Atrial fibrillation is more common in patients with PAD than in the general population.28,29  Data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry indicated a high prevalence of PAD coexisting with AF.30  The 2 diseases have common risk factors and epidemiological characteristics, and the coexistence of these conditions significantly increases the risk of major adverse events (including stroke, myocardial infarction, cardiovascular death, and all-cause death).22,31  In an observational study based on global risk assessment of AF in older women, Perez et al32  found that PAD was independently associated with a high incidence of AF. The Multi-Ethnic Study of Atherosclerosis33  and Cardiovascular Health Study34  also confirmed this relationship. The authors found that PAD remained an independent risk factor for AF after adjusting for factors such as age, sex, ethnicity, and cardiovascular disease. In addition, studies have shown that the risk of AF increases as the value of the ABI decreased.33,35  Bekwelem et al36  found that the relationship between PAD and AF may be mainly related to traditional atherosclerotic risk factors. Atherosclerosis and AF have several similar risk factors and have both been associated with elevated levels of proinflammatory cytokines, endothelial dysfunction, and platelet-mediated thrombosis.3739  Theses common risk factors may explain why PAD was observed as a risk factor of CIED-AF in this study.

Previous studies have shown a linear increase in the cumulative percentage of VP and the risk of AF.40,41  Cheung et al13  studied patients with different indications for dual-chamber pacemaker implantation and found that in patients with sinus node dysfunction and a dual-chamber pacemaker, cumulative VP ≥50% is related to the elevated occurrence risk of AF by 2-fold. In combination with previous studies, it was speculated that AP-VP pacing may enhance myocardial cell extension, atrial fibrosis, and destruction of intercellular coupling, thereby promoting the remodeling of the atrium. In addition, right ventricular pacing may lead to mechanical desynchronization of the heart. This desynchronization will impair left ventricular function, change hemodynamics, gradually increase LA pressure, and further promote atrial myocyte electrical remodeling, which may cause CIED-AF.4245 

Consistent with previous studies, the findings of this study revealed that advanced age could contribute to the development of new-onset AF.7  Several possible mechanisms may explain the relationship between AF and age. Atrial fibrosis, which is an important structural basis for AF, increases with ages.46,47  This may be one of the causes of AF in older adult patients with dual-chamber pacemakers. In addition, 1 study found that aging may be the most important risk factor affecting the stability of the cardiovascular internal environment.48 

This study also indicated that increased LA diameter could contribute to the development of new-onset AF.49  The following mechanisms may explain the relationship between increased LA diameter and new-onset AF. On one hand, CIED implantation may directly induce cardiac fibrosis and atrial expansion, which lead to cardiac remodeling and reentry loop formation and, eventually, to AF. On the other hand, CIED implantation may trigger tachycardia, which may promote atrial contraction dysfunction and induce atrial dilation.50  Atrial dilation promotes atrial remodeling and atrial fibrosis by increasing the diastolic length of atrial muscle cells, which triggers AF.51 

To the authors' knowledge, this is the first study to establish a nomogram-illustrated model to evaluate the risk of new-onset AF after CIED implantation in a Chinese population. This nomogram may be a convenient tool for clinicians to identify patients at high risk for new-onset AF early after dual-chamber pacemaker implantation. Early recognition of patients at high risk for new-onset AF may be helpful for AF prevention management and prognosis improvement. By applying the nomogram, the risk factors can be controlled, thus reducing the incidence of new-onset AF. The probabilities derived from the nomogram can also be used prospectively to evaluate the effects and outcomes of long-term primary prevention for patients at high risk for developing AF after dual-chamber pacemaker implantation. In addition, some scholars believe that SCAF may be the direct cause of stroke, whereas others consider SCAF to be only a risk factor for stroke. Being able to assess the risk of AF through the nomogram may allow clinicians to enhance the frequency of programmed follow-up for high-risk patients to reduce the rate of missed diagnosis. More timely information on the occurrence of SCAF and its complications (eg, stroke and HF) can be provided, and potential mechanisms can be further revealed.

This study had several limitations. First, the data were collected retrospectively in a single center, and the sample size was small. The included independent variables cannot completely cover all AF risk factors. As a result, the predictive power of the model was limited. Second, categorical variables were used to build a line chart to ensure that the nomogram is an easy-to-use clinical tool. Compared with the use of continuous variables, this simplicity may partially sacrifice the effectiveness of prognostic risk prediction.52  Third, this study used self-service internal verification. Although this is an acceptable method of negotiating chart development and verification, external validation is still needed to test its versatility. Fourth, there may be inadequate detection conditions for the variables involved in this study. For example, not every patient was tested for ABI after admission, which may lead to a missed PAD diagnosis in some patients. In addition, LA examination only involved LA diameter. Including LA volume and LA function measurements may make the predictive model more accurate. Therefore, further research is needed to supplement the follow-up information, increase the sample size, and select more independent variables to reflect the risk of new-onset AF after pacemaker implantation. This will help to improve the predictive ability of the model.

In conclusion, the authors established and validated an original nomogram that can be conveniently used to identify the risk of new-onset AF in patients after dual-chamber pacemaker implantation in a Chinese population. The proposed nomogram incorporating PAD, AP-VP ≥50%, age, and increased LA diameter may be a valuable tool for clinicians in making decisions and implementing interventions with clinical practical utility.

Author Contributions: Y.Y. and G.F. drafted the study protocol and design. J.L., Z.S., and C.S. performed the data sorting and input and data collection. F.X., J.T., and J.J. contributed to refinement of the data collection tools and design of follow-up procedures. J.L., C.X., and Z.S. performed statistical analysis and were responsible for daily research management. Y.Y. and J.L. prepared and edited the manuscript. Y.Y. is the principal investigator. All authors read and approved the final manuscript.

Conflict of Interest Disclosures: The authors declare that they have no competing interests.

Funding/Support: This work was supported by the Medical Health Science and Technology program of Zhejiang Province (grants 2018KY492 and 2020KY165), the project supported by Zhejiang Provincial Natural Science Foundation of China (grant No. LY21H020006), and the Clinical Research Fund Project of Zhejiang Medical Association (funding for cardiovascular and cerebrovascular diseases, grant No. 2018ZYC-A13).

Availability of Data and Materials: The data sets used during the current study are available from the corresponding author upon reasonable request.

1.
Lloyd-Jones
DM
,
Wang
TJ
,
Leip
EP
,
et al.
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study
.
Circulation.
2004
;
110
(
9
):
1042
1046
.
doi:
10.1161/01.CIR.0000140263.20897.42
2.
Feigin
VL
,
Forouzanfar
MH
,
Krishnamurthi
R
,
et al.
Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010
.
Lancet.
2014
;
383
(
9913
):
245
254
.
doi:
10.1016/s0140-6736(13)61953-4
3.
Sanna
T
,
Diener
HC
,
Passman
RS
,
et al.
Cryptogenic stroke and underlying atrial fibrillation
.
N Engl J Med.
2014
;
370
(
26
):
2478
2486
.
doi:
10.1056/NEJMoa1313600
4.
Brachmann
J
,
Morillo
CA
,
Sanna
T
,
et al.
Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the cryptogenic stroke and underlying atrial fibrillation trial
.
Circ Arrhythm Electrophysiol.
2016
;
9
(
1
):
e003333
.
doi:
10.1161/CIRCEP.115.003333
5.
Gladstone
DJ
,
Spring
M
,
Dorian
P
,
et al.
Atrial fibrillation in patients with cryptogenic stroke
.
N Engl J Med.
2014
;
370
(
26
):
2467
2477
.
doi:
10.1056/NEJMoa1311376
6.
Mahajan
R
,
Perera
T
,
Elliott
AD
,
et al.
Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis
.
Eur Heart J.
2018
;
39
(
16
):
1407
1415
.
doi:
10.1093/eurheartj/ehx731
7.
Boriani
G
,
Glotzer
TV
,
Ziegler
PD
,
et al.
Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden
.
Heart Rhythm.
2018
;
15
(
3
):
376
383
.
doi:
10.1016/j.hrthm.2017.11.007
8.
Wong
JA
,
Conen
D
,
Van Gelder
IC
, et al.
Progression of device-detected subclinical atrial fibrillation and the risk of heart failure
.
J Am Coll Cardiol.
2018
;
71
(
23
):
2603
2611
.
doi:
10.1016/j.jacc.2018.03.519
9.
Van Gelder
IC
,
Healey
JS
,
Crijns
H
,
et al.
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
.
Eur Heart J.
2017
;
38
(
17
):
1339
1344
.
doi:
10.1093/eurheartj/ehx042
10.
Nishinarita
R
,
Niwano
S
,
Fukaya
H
,
et al.
Burden of implanted-device-detected atrial high-rate episode is associated with future heart failure events—clinical significance of asymptomatic atrial fibrillation in patients with implantable cardiac electronic devices
.
Circ J.
2019
;
83
(
4
):
736
742
.
doi:
10.1253/circj.CJ-18-1130
11.
Ogino
Y
,
Ishikawa
T
,
Ishigami
T
,
et al.
Characteristics and prognosis of pacemaker-identified new-onset atrial fibrillation in Japanese people
.
Circ J.
2017
;
81
(
6
):
794
798
.
doi:
10.1253/circj.CJ-16-1018
12.
Israel
C
,
Kitsiou
A
,
Kalyani
M
,
et al.
Detection of atrial fibrillation in patients with embolic stroke of undetermined source by prolonged monitoring with implantable loop recorders
.
Thromb Haemost.
2017
;
117
(
10
):
1962
1969
.
doi:
10.1160/TH17-02-0072
13.
Cheung
JW
,
Keating
RJ
,
Stein
KM
,
et al.
Newly detected atrial fibrillation following dual chamber pacemaker implantation
.
J Cardiovasc Electrophysiol.
2006
;
17
(
12
):
1323
1328
.
doi:
10.1111/j.1540-8167.2006.00648.x
14.
Sade
LE
,
Atar
I
,
Ozin
B
,
Yuce
D
,
Muderrisoglu
H.
Determinants of new-onset atrial fibrillation in patients receiving CRT: mechanistic insights from speckle tracking imaging
.
JACC Cardiovasc Imaging.
2016
;
9
(
2
):
99
111
.
doi:
10.1016/j.jcmg.2015.05.011
15.
Caulfield
S
,
Menezes
G
,
Marignol
L
,
Poole
C.
Nomograms are key decision-making tools in prostate cancer radiation therapy
.
Urol Oncol.
2018
;
36
(
6
):
283
292
.
doi:
10.1016/j.urolonc.2018.03.017
16.
Balachandran
VP
,
Gonen
M
,
Smith
JJ
,
DeMatteo
RP.
Nomograms in oncology: more than meets the eye
.
Lancet Oncol.
2015
;
16
(
4
):
e173
e180
.
doi:
10.1016/S1470-2045(14)71116-7
17.
Grimes
DA.
The nomogram epidemic: resurgence of a medical relic
.
Ann Intern Med.
2008
;
149
(
4
):
273
275
.
doi:
10.7326/0003-4819-149-4-200808190-00010
18.
Chun
FK
,
Karakiewicz
PI
,
Briganti
A
,
et al.
A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer
.
BJU Int.
2007
;
99
(
4
):
794
800
.
doi:
10.1111/j.1464-410X.2006.06694.x
19.
Gandaglia
G
,
Ploussard
G
,
Valerio
M
,
et al.
A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies
.
Eur Urol.
2019
;
75
(
3
):
506
514
.
doi:
10.1016/j.eururo.2018.10.012
20.
Jehi
L
,
Yardi
R
,
Chagin
K
,
et al.
Development and validation of nomograms to provide individualised predictions of seizure outcomes after epilepsy surgery: a retrospective analysis
.
Lancet Neurol.
2015
;
14
(
3
):
283
290
.
doi:
10.1016/S1474-4422(14)70325-4
21.
Hartaigh
,
Gransar
H
,
Callister
T
,
et al.
Development and validation of a simple-to-use nomogram for predicting 5-, 10-, and 15-year survival in asymptomatic adults undergoing coronary artery calcium scoring
.
JACC Cardiovasc Imaging.
2018
;
11
(
3
):
450
458
.
doi:
10.1016/j.jcmg.2017.03.018
22.
Aboyans
V
,
Ricco
JB
,
Bartelink
MEL
, et al;
ESC Scientific Document Group
.
2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)
.
Eur Heart J.
2018
;
39
(
9
):
763
816
.
doi:
10.1093/eurheartj/ehx095
23.
Gorenek
BC
,
Bax
J
,
Boriani
G
,
et al.
Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE)
.
Europace.
2017
;
19
(
9
):
1556
1578
.
doi:
10.1093/europace/eux163
24.
Hess
PL
,
Healey
JS
,
Granger
CB
,
et al.
The role of cardiovascular implantable electronic devices in the detection and treatment of subclinical atrial fibrillation: a review
.
JAMA Cardiol.
2017
;
2
(
3
):
324
331
.
doi:
10.1001/jamacardio.2016.5167
25.
Healey
JS
,
Connolly
SJ
,
Gold
MR
,
et al.
Subclinical atrial fibrillation and the risk of stroke
.
N Engl J Med.
2012
;
366
(
2
):
120
129
.
doi:
10.1056/NEJMoa1105575
26.
Noseworthy
PA
,
Kaufman
ES
,
Chen
LY
,
et al.
Subclinical and device-detected atrial fibrillation: pondering the knowledge gap: a scientific statement from the American Heart Association
.
Circulation.
2019
;
140
(
25
):
e944
e963
.
doi:
10.1161/CIR.0000000000000740
27.
Kim
BS
,
Chun
KJ
,
Hwang
JK
,
et al.
Predictors and long-term clinical outcomes of newly developed atrial fibrillation in patients with cardiac implantable electronic devices
.
Medicine (Baltimore).
2016
;
95
(
28
):
e4181
.
doi:
10.1097/MD.0000000000004181
28.
Goto
S
,
Bhatt
DL
,
Rother
J
,
et al.
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis
.
Am Heart J.
2008
;
156
(
5
):
855
863
,
863.e2
.
doi:
10.1016/j.ahj.2008.06.029
29.
Naccarelli
GV
,
Varker
H
,
Lin
J
,
Schulman
KL.
Increasing prevalence of atrial fibrillation and flutter in the United States
.
Am J Cardiol.
2009
;
104
(
11
):
1534
1539
.
doi:
10.1016/j.amjcard.2009.07.022
30.
Winkel
TA
,
Hoeks
SE
,
Schouten
O
,
et al.
Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry
.
Eur J Vasc Endovasc Surg.
2010
;
40
(
1
):
9
16
.
doi:
10.1016/j.ejvs.2010.03.003
31.
Kirchhof
P
,
Benussi
S
,
Kotecha
D
,
et al.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
.
Eur J Cardiothorac Surg.
2016
;
50
(
5
):
e1
e88
.
doi:
10.1093/ejcts/ezw313
32.
Perez
MV
,
Wang
PJ
,
Larson
JC
,
et al.
Risk factors for atrial fibrillation and their population burden in postmenopausal women: the Women's Health Initiative Observational Study
.
Heart.
2013
;
99
(
16
):
1173
1178
.
doi:
10.1136/heartjnl-2013-303798
33.
O'Neal
WT
,
Efird
JT
,
Nazarian
S
,
Alonso
A
,
Heckbert
SR
,
Soliman
EZ.
Peripheral arterial disease and risk of atrial fibrillation and stroke: the Multi-Ethnic Study of Atherosclerosis
.
J Am Heart Assoc.
2014
;
3
(
6
):
e001270
.
doi:
10.1161/JAHA.114.001270
34.
Furberg
CD
,
Psaty
BM
,
Manolio
TA
,
Gardin
JM
,
Smith
VE
,
Rautaharju
PM.
Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study)
.
Am J Cardiol.
1994
;
74
(
3
):
236
241
.
doi:
10.1016/0002-9149(94)90363-8
35.
Griffin
WF
,
Salahuddin
T
,
O'Neal
WT
,
Soliman
EZ.
Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly
.
Europace.
2016
;
18
(
6
):
794
798
.
doi:
10.1093/europace/euv369
36.
Bekwelem
W
,
Norby
FL
,
Agarwal
SK
,
et al.
Association of peripheral artery disease with incident atrial fibrillation: the ARIC (Atherosclerosis Risk in Communities) Study
.
J Am Heart Assoc.
2018
;
7
(
8
):
e007452
.
doi:
10.1161/JAHA.117.007452
37.
da Silva
RM.
Influence of inflammation and atherosclerosis in atrial fibrillation
.
Curr Atheroscler Rep.
2017
;
19
(
1
):
2
.
doi:
10.1007/s11883-017-0639-0
38.
Fuster
V
,
Moreno
PR
,
Fayad
ZA
,
Corti
R
,
Badimon
JJ.
Atherothrombosis and high-risk plaque: part I: evolving concepts
.
J Am Coll Cardiol.
2005
;
46
(
6
):
937
954
.
doi:
10.1016/j.jacc.2005.03.074
39.
Watson
T
,
Shantsila
E
,
Lip
GY.
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited
.
Lancet.
2009
;
373
(
9658
):
155
166
.
doi:
10.1016/S0140-6736(09)60040-4
40.
Sweeney
MO
,
Hellkamp
AS.
Heart failure during cardiac pacing
.
Circulation.
2006
;
113
(
17
):
2082
2088
.
doi:
10.1161/CIRCULATIONAHA.105.608356
41.
Sweeney
MO
,
Bank
AJ
,
Nsah
E
,
et al.
Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease
.
N Engl J Med.
2007
;
357
(
10
):
1000
1008
.
doi:
10.1056/NEJMoa071880
42.
Stojnić
BB
,
Stojanov
PL
,
Angelkov
L
,
Pavlovic
SU
,
Radjen
GS
,
Velimirovic
DB.
Evaluation of asynchronous left ventricular relaxation by Doppler echocardiography during ventricular pacing with AV synchrony (VDD): comparison with atrial pacing (AAI)
.
Pacing Clin Electrophysiol.
1996
;
19
(
6
):
940
944
.
doi:
10.1111/j.1540-8159.1996.tb03390.x
43.
Lee
MA
,
Dae
MW
,
Langberg
JJ
,
et al.
Effects of long-term right ventricular apical pacing on left ventricular perfusion, innervation, function and histology
.
J Am Coll Cardiol.
1994
;
24
(
1
):
225
232
.
doi:
10.1016/0735-1097(94)90567-3
44.
Wijffels
MC
,
Kirchhof
CJ
,
Dorland
R
,
Power
J
,
Allessie
MA.
Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation
.
Circulation.
1997
;
96
(
10
):
3710
3720
.
doi:
10.1161/01.cir.96.10.3710
45.
Gülker
H.
A summary of the acute effects of falipamil in man
.
Eur Heart J.
1987
;
8 suppl L
:
141
146
.
doi:
10.1093/eurheartj/8.suppl_l.141
46.
Gramley
F
,
Lorenzen
J
,
Knackstedt
C
,
et al.
Age-related atrial fibrosis
.
Age (Dordr).
2009
;
31
(
1
):
27
38
.
doi:
10.1007/s11357-008-9077-9
47.
Heijman
J
,
Algalarrondo
V
,
Voigt
N
,
et al.
The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis
.
Cardiovasc Res.
2016
;
109
(
4
):
467
479
.
doi:
10.1093/cvr/cvv275
48.
Kovacic
JC
,
Moreno
P
,
Hachinski
V
,
Nabel
EG
,
Fuster
V.
Cellular senescence, vascular disease, and aging: part 1 of a 2-part review
.
Circulation.
2011
;
123
(
15
):
1650
1660
.
doi:
10.1161/CIRCULATIONAHA.110.007021
49.
Kaufman
ES
,
Israel
CW
,
Nair
GM
,
et al.
Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT
.
Heart Rhythm.
2012
;
9
(
8
):
1241
1246
.
doi:
10.1016/j.hrthm.2012.03.017
50.
Shi
Y
,
Ducharme
A
,
Li
D
,
Gaspo
R
,
Nattel
S
,
Tardif
JC.
Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation
.
Cardiovasc Res.
2001
;
52
(
2
):
217
225
.
doi:
10.1016/s0008-6363(01)00377-7
51.
De Jong
AM
,
Maass
AH
,
Oberdorf-Maass
SU
,
Van Veldhuisen
DJ
,
Van Gilst
WH
,
Van Gelder
IC.
Mechanisms of atrial structural changes caused by stretch occurring before and during early atrial fibrillation
.
Cardiovasc Res.
2011
;
89
(
4
):
754
765
.
doi:
10.1093/cvr/cvq357
52.
Royston
P
,
Altman
DG.
External validation of a Cox prognostic model: principles and methods
.
BMC Med Res Methodol.
2013
;
13
:
33
.
doi:
10.1186/1471-2288-13-33